Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis
NG Daver, S Iqbal, C Renard, RJ Chan… - Journal of Hematology & …, 2023 - Springer
Background TP53 mutations, which are present in 5% to 10% of patients with acute myeloid
leukemia (AML), are associated with treatment resistance and poor outcomes. First-line …
leukemia (AML), are associated with treatment resistance and poor outcomes. First-line …
Role of biomarkers in the management of acute myeloid leukemia
S Small, TS Oh, LC Platanias - International journal of molecular sciences, 2022 - mdpi.com
Despite many recent advances in treatment options, acute myeloid leukemia (AML) still has
a high mortality rate. One important issue in optimizing outcomes for AML patients lies in the …
a high mortality rate. One important issue in optimizing outcomes for AML patients lies in the …
Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics
BZ Carter, PY Mak, W Tao, E Ayoub… - Blood cancer …, 2023 - nature.com
TP53-mutant acute myeloid leukemia (AML) respond poorly to currently available
treatments, including venetoclax-based drug combinations and pose a major therapeutic …
treatments, including venetoclax-based drug combinations and pose a major therapeutic …
Targeting the mevalonate or Wnt pathways to overcome CAR T-cell resistance in TP53-mutant AML cells
TP53-mutant acute myeloid leukemia (AML) and myelodysplastic neoplasms (MDS) are
characterized by chemotherapy resistance and represent an unmet clinical need. Chimeric …
characterized by chemotherapy resistance and represent an unmet clinical need. Chimeric …
TP53 mutations in AML patients are associated with dismal clinical outcome irrespective of frontline induction regimen and allogeneic hematopoietic cell …
Simple Summary TP53 mutations are adverse-risk genetic aberrations in acute myeloid
leukemia (AML). The optimal treatment approach in patients with TP53-mutated (TP53 MUT) …
leukemia (AML). The optimal treatment approach in patients with TP53-mutated (TP53 MUT) …
Lower-intensity CPX-351 plus venetoclax induction for adults with newly diagnosed AML unfit for intensive chemotherapy
GL Uy, V Pullarkat, P Baratam, RK Stuart… - Blood …, 2024 - ashpublications.org
Preclinical data suggest a rationale for combining CPX-351, a dual-drug liposomal
encapsulation of daunorubicin and cytarabine, with venetoclax, a B-cell lymphoma-2 …
encapsulation of daunorubicin and cytarabine, with venetoclax, a B-cell lymphoma-2 …
Continued decitabine/all-trans retinoic acid treatment: extended complete remission in an elderly AML patient with multi-hit TP53 lesions and complex-monosomal …
J Thomas, UU Rehman, H Bresser, O Grishina… - Clinical …, 2024 - Springer
DNA-hypomethylating agents (HMAs) induce notable remission rates in AML/MDS patients
with TP53 mutations; however, secondary resistance often develops rapidly. In the …
with TP53 mutations; however, secondary resistance often develops rapidly. In the …
What's next after hypomethylating agents failure in myeloid neoplasms? a rational approach
Simple Summary The hypomethylating agents (HMA) azacitidine and decitabine are among
the standard treatment options for myeloid neoplasms. However, the treatment of patients …
the standard treatment options for myeloid neoplasms. However, the treatment of patients …
Niclosamide combined to Azacitidine to target TP53-mutated MDS/AML cells
N Maslah, S Rety, M Bonnamy, L Aguinaga, T Huynh… - Leukemia, 2024 - nature.com
Myelodysplastic syndromes (MDS) are malignant bone marrow disorders characterized by
ineffective hematopoiesis leading to refractory cytopenias and an increased risk of …
ineffective hematopoiesis leading to refractory cytopenias and an increased risk of …
Impact of TP53 Mutation Status in Elderly AML Patients When Adding All‐Trans Retinoic Acid or Valproic Acid to Decitabine
H Bresser, C Schmoor, O Grishina… - European journal of …, 2024 - Wiley Online Library
In a randomized phase II trial (AMLSG 14‐09, NCT00867672) of elderly, newly diagnosed
AML patients, ATRA combined with decitabine (DEC) significantly improved the overall …
AML patients, ATRA combined with decitabine (DEC) significantly improved the overall …